Overview

Talimogene Laherparepvec (T-VEC) for Breast Cancer Local Recurrence

Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if talimogene laherparepvec can help to control recurrent breast cancer. The safety of this drug will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Amgen